ANIK Anika Therapeutics, Inc. Insider Trading

Director John Henneman purchases 5,000 shares of Anika Therapeutics amid revenue decline and ongoing losses.

John Henneman, a board member at Anika Therapeutics, purchased 5,000 shares at a time when the company is facing financial headwinds — revenue declined year-over-year and the company remains unprofitable with consecutive quarterly losses. The stock has recovered substantially from its lows and is now trading within reach of its recent highs, making this purchase notable because director buying typically signals conviction during weakness rather than after a significant rally. While the transaction size is modest relative to his holdings, the timing suggests either confidence that the turnaround is underway or simply a routine portfolio move that doesn't necessarily reflect a major conviction call. Investors should monitor whether this purchase signals Henneman's belief that the market has overshot the downside risk, or whether additional directors follow with similar buying patterns.

ANIK President/CEO bought 12,200 shares ($149.9K) at $12.29; holdings +50.9% to 36.2K shares amid unprofitable year

Griffin Stephen D., President and CEO of Anika Therapeutics, purchased 12,200 shares at $12.29 on 2026-04-30, increasing his holdings by 50.9% to 36,163 shares. The timing is notable given that the company posted net income of $-5,056,000.00 for its most recent full fiscal year and annual revenue declined 5.9% year-over-year. The purchase occurred while the stock trades -22.2% from its 52-week high and has declined 14.1% over the preceding 30 days, though it is up 34.9% over 90 days. An insider purchase of this magnitude from the company's top executive warrants attention to whether he views the depressed valuation as an opportunity, though the negative financial performance and revenue contraction present a countervailing risk signal that investors should weigh carefully.